LONDON, Dec. 1 -- The government of the United Kingdom issued the following news:
Following monitoring of pharmacovigilance data, sections 3.6 and 3.9 of the Summary of Product Characteristics (SPC) for DIVENCE IBR MARKER LIVELyophilisateand Solvent for Suspension for Injection (Cattle) have been updated.
Section 3.6 Adverse events now states: milk production decrease, reduced food intake and decreased activity as uncommon (1 to 10 animals/10,000 animals treated).
Section 3.9 Administration routes and dosage now states: Allow the vaccine to reach a temperature of 15 degC - 25 degC before administration.
Any veterinary medicinal product which is authorised for marketing in the United Kingdom will have its Summary of Product Characteristics (SPC) available on our Product Information Database.
No medicine is 100% risk free, the SPC includes information on what adverse events have been known to occur following administration of a particular product, these can be found in either section Adverse events (3.6) or Adverse reactions (4.6).
All updates to SPCs other than template changes, are published in the medicine updates section of VMD Connect.
Disclaimer: Curated by HT Syndication.
